Epitopea Appoints Lisa Butterfield
Analysis based on 6 articles · First reported Apr 13, 2026 · Last updated Apr 14, 2026
The appointment of Lisa Butterfield to Epitopea's Scientific Advisory Board is expected to positively impact Epitopea's valuation and prospects, as her expertise strengthens the company's ability to advance its RNA-based cancer immunotherapies. This development signals potential progress in the biotechnology sector, particularly for companies focused on hard-to-treat solid tumors.
Epitopea, a transatlantic cancer immunotherapeutics company, announced the appointment of Lisa Butterfield to its Scientific Advisory Board on April 13, 2026. Dr. Butterfield is a highly respected leader in immuno-oncology with extensive expertise in cancer vaccines, immune profiling, biomarker development, and cellular therapies for solid tumor types. Her appointment is expected to strengthen Epitopea's scientific strategy as it advances its pipeline of RNA-based cancer immunotherapies, including its lead candidate CryptiVax-1001 for high-grade serous ovarian cancer. Dr. Butterfield's background includes roles at Merck & Co., the University of California, San Francisco, the Parker Institute for Cancer Immunotherapy, and the University of Pittsburgh. She also served as President of the Society for Immunotherapy of Cancer and chaired the United States — Food and Drug Administration's Cell, Tissue and Gene Therapy Advisory Committee.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard